131 related articles for article (PubMed ID: 24843717)
21. C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test.
Iwasaki Y; Kondo K; Hasegawa H; Oiso Y
Diabetes Res; 1994; 25(3):129-37. PubMed ID: 7671552
[TBL] [Abstract][Full Text] [Related]
22. Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment.
Araki H; Tanaka Y; Yoshida S; Morita Y; Kume S; Isshiki K; Araki S; Uzu T; Kashiwagi A; Maegawa H
J Diabetes Investig; 2014 Jul; 5(4):435-41. PubMed ID: 25411603
[TBL] [Abstract][Full Text] [Related]
23. A study of serum free C-peptide responses to oral glucose load in diabetic patients: with special reference to types of diabetes and methods of treatment.
Hsieh SD; Akanuma Y; Takaku F
Tohoku J Exp Med; 1984 Mar; 142(3):249-60. PubMed ID: 6374968
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors for the efficacy of switch to oral hypoglycemic agents in Japanese type 2 diabetic patients with intensive insulin therapy temporarily introduced.
Yamamoto Y; Takahara M; Yasuda T; Katakami N; Matsuoka TA; Kaneto H; Shimomura I
Endocr J; 2014; 61(9):911-9. PubMed ID: 25048394
[TBL] [Abstract][Full Text] [Related]
25. Analysis of factors influencing postprandial C-peptide levels in Japanese patients with type 2 diabetes: Comparison with C-peptide levels after glucagon load.
Funakoshi S; Fujimoto S; Hamasaki A; Fujiwara H; Fujita Y; Ikeda K; Takahara S; Seino Y; Inagaki N
J Diabetes Investig; 2011 Nov; 2(6):429-34. PubMed ID: 24843526
[TBL] [Abstract][Full Text] [Related]
26. [Short-term intensive insulin therapy as a method of overcoming secondary failure of sulfonylureas in patients with type 2 diabetes (non-insulin-dependent)].
Jedynasty K; Kasperska-Czyzykowa T; Stepień K; Nowaczyk R
Pol Arch Med Wewn; 1998 Jun; 99(6):442-51. PubMed ID: 10085698
[TBL] [Abstract][Full Text] [Related]
27. Secondary failure to oral hypoglycaemic agents in non-obese patients with non-insulin-dependent diabetes is related to reduced insulin release.
Pontiroli AE; Calderara A; Maffi P; Bonisolli L; Carenini A; Piatti PM; Monti LD; Gallus G; Pozza G; Illeni MT
Diabete Metab; 1989; 15(2):79-84. PubMed ID: 2661281
[TBL] [Abstract][Full Text] [Related]
28. Preoperative insulin secretion ability and pancreatic parenchymal thickness as useful parameters for predicting postoperative insulin secretion in patients undergoing pancreaticoduodenectomy.
Yoshikawa A; Kozawa J; Okita K; Yoneda S; Okauchi Y; Uno S; Iwahashi H; Ohira T; Takiuchi D; Eguchi H; Takeda Y; Imagawa A; Shimomura I
Endocr J; 2012; 59(5):383-92. PubMed ID: 22374239
[TBL] [Abstract][Full Text] [Related]
29. Stimulated C-peptide and glucose levels as metabolic criteria to use insulin treatment in adult-onset type II diabetes.
Lee A; Bray GA; Morley JE
Endocr Pract; 1996; 2(3):183-90. PubMed ID: 15251537
[TBL] [Abstract][Full Text] [Related]
30. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
[TBL] [Abstract][Full Text] [Related]
31. EADSG Guidelines: Insulin Therapy in Diabetes.
Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
[TBL] [Abstract][Full Text] [Related]
32. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects.
Kawamori R; Bando K; Yamasaki Y; Kubota M; Watarai T; Iwama N; Shichiri M; Kamada T
Diabetes Care; 1989; 12(10):680-5. PubMed ID: 2515048
[TBL] [Abstract][Full Text] [Related]
33. Serum free C-peptide response to oral glucose loading as a parameter for the monitoring of pancreatic B-cell function in diabetic patients.
Hsieh SD; Kanazawa Y; Akanuma Y
Diabetes Res Clin Pract; 1985 Aug; 1(2):109-14. PubMed ID: 3915258
[TBL] [Abstract][Full Text] [Related]
34. Glucagon-stimulated and postprandial plasma C-peptide values as measures of insulin secretory capacity.
Koskinen PJ; Viikari JS; Irjala KM
Diabetes Care; 1988 Apr; 11(4):318-22. PubMed ID: 3042307
[TBL] [Abstract][Full Text] [Related]
35. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
36. C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study.
Ohbatake A; Yagi K; Karashima S; Shima Y; Miyamoto Y; Asaka H; Okazaki S; Kometani M; Kawashiri MA; Takeda Y; Yoneda T; Chujo D
Diabetes Ther; 2019 Apr; 10(2):673-681. PubMed ID: 30788807
[TBL] [Abstract][Full Text] [Related]
37. Postprandial serum C-peptide to plasma glucose concentration ratio correlates with oral glucose tolerance test- and glucose clamp-based disposition indexes.
Okuno Y; Komada H; Sakaguchi K; Nakamura T; Hashimoto N; Hirota Y; Ogawa W; Seino S
Metabolism; 2013 Oct; 62(10):1470-6. PubMed ID: 23831440
[TBL] [Abstract][Full Text] [Related]
38. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
39. Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes: a possible link suggested by cross-sectional analysis.
Saisho Y; Tanaka K; Abe T; Shimada A; Kawai T; Itoh H
Endocr J; 2012; 59(3):187-95. PubMed ID: 22156325
[TBL] [Abstract][Full Text] [Related]
40. Analysis of insulin secretion based on changes in plasma insulin and C-peptide in man.
Sakai T; Ohneda A; Nihei J; Kobayashi T
Tohoku J Exp Med; 1982 Dec; 138(4):427-40. PubMed ID: 6761899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
